Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA

AIM: Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies (DMTs). PATIENTS & METHODS: Retrospective, observational study of IBM(®)MarketScan(®) cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Araujo, Lita, Kyatham, Srikanth, Bzdek, Kristen G, Higuchi, Keiko, Greene, Nupur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288951/
https://www.ncbi.nlm.nih.gov/pubmed/36440609
http://dx.doi.org/10.2217/cer-2022-0127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288951/
https://www.ncbi.nlm.nih.gov/pubmed/36440609
http://dx.doi.org/10.2217/cer-2022-0127

Ejemplares similares